Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)

VOLUNTARY ANNOUNCEMENT
H SHARE REPURCHASE PLAN

Reference is made to the circular of Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**") dated April 27, 2026 (the "**Circular**") and the poll results announcement of the Company dated May 28, 2026 relating to, among other things, the grant of the Repurchase Mandate. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Circular.

On May 28, 2026, the Company held the 2025 annual general meeting, at which a resolution on the grant of the Repurchase Mandate to the Board of Directors (the "**Board**") for repurchase of H Shares was considered and approved.

Upon comprehensively considering the Group's current operating conditions, financial position, and future development prospects, the Board believes that the current trading price of the shares does not reflect their intrinsic value. Conducting an H share repurchase under the current market conditions demonstrates the Company's strong confidence in its business outlook and growth. The H Share repurchase plan outlined below will help enhance shareholder returns and preserve the Company's value, and is in the best interests of the Company and its shareholders as a whole.

The Board considered and approved the H Share repurchase plan with a total repurchase amount of not more than HKD100 million for the repurchase of no more than 1 million H Shares (the "**H Share Repurchase Plan**") in accordance with the Repurchase Mandate. The H Share Repurchase Plan will be funded entirely by the Company's own resources, ensuring financial stability without reliance on external financing. The H Shares repurchased under the H Share Repurchase Plan may be held as treasury shares or cancelled of in accordance with the Listing Rules and any applicable rules and regulations.

The Company will proceed with H Share Repurchase Plan in compliance with the Repurchase Mandate commencing from the date of this announcement (subject to completion of the applicable administration procedures) until May 27, 2027, any repurchase made will be conducted in compliance with the articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs and all other applicable consents, laws and regulations to which the Company is subject to.

Shareholders and potential investors of the Company are advised that the implementation of the H Share Repurchase Plan is subject to the sole discretion of the Directors based on the market conditions and that no assurance can be given as to the timing, quantity or price of any repurchase. As such, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, June 29, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.